Neeraj Dhar

List of Publications by Year
in descending order

61 papers	4,869 citations	109137 35 h-index	133063 59 g-index
88 all docs	88 docs citations	88 times ranked	5295 citing authors

#	Article	IF	Citations
1	Mycobacterium tuberculosis EspK Has Active but Distinct Roles in the Secretion of EsxA and EspB. Journal of Bacteriology, 2022, 204, e0006022.	1.0	10
2	Single-Cell Analysis of Mycobacteria Using Microfluidics and Time-Lapse. Methods in Molecular Biology, 2021, 2314, 205-229.	0.4	2
3	Rapid endotheliitis and vascular damage characterize SARSâ€CoVâ€2 infection in a human lungâ€onâ€chip model. EMBO Reports, 2021, 22, e52744.	2.0	81
4	Revealing Antibiotic Tolerance of the Mycobacterium smegmatis Xanthine/Uracil Permease Mutant Using Microfluidics and Single-Cell Analysis. Antibiotics, 2021, 10, 794.	1.5	5
5	Dynamic persistence of UPEC intracellular bacterial communities in a human bladder-chip model of urinary tract infection. ELife, 2021, 10, .	2.8	47
6	Early invasion of the bladder wall by solitary bacteria protects UPEC from antibiotics and neutrophil swarms in an organoid model. Cell Reports, 2021, 36, 109351.	2.9	13
7	Computational Analysis of the Mutual Constraints between Singleâ€Cell Growth and Division Control Models. Advanced Biology, 2020, 4, 1900103.	3.0	9
8	A lung-on-chip model of early Mycobacterium tuberculosis infection reveals an essential role for alveolar epithelial cells in controlling bacterial growth. ELife, 2020, 9, .	2.8	88
9	Driving polar growth. ELife, 2020, 9, .	2.8	0
10	Preexisting variation in DNA damage response predicts the fate of single mycobacteria under stress. EMBO Journal, 2019, 38, e101876.	3.5	27
11	Fluorescent Benzothiazinone Analogues Efficiently and Selectively Label Dpre1 in Mycobacteria and Actinobacteria. ACS Chemical Biology, 2018, 13, 3184-3192.	1.6	16
12	Elucidating the role of (p)ppGpp in mycobacterial persistence against antibiotics. IUBMB Life, 2018, 70, 836-844.	1.5	28
13	Dielectrophoresis as a single cell characterization method for bacteria. Biomedical Physics and Engineering Express, 2017, 3, 015005.	0.6	21
14	An Amidase_3 domain-containing N-acetylmuramyl-L-alanine amidase is required for mycobacterial cell division. Scientific Reports, 2017, 7, 1140.	1.6	26
15	Division site selection linked to inherited cell surface wave troughs in mycobacteria. Nature Microbiology, 2017, 2, 17094.	5.9	61
16	The Inosine Monophosphate Dehydrogenase, GuaB2, Is a Vulnerable New Bactericidal Drug Target for Tuberculosis. ACS Infectious Diseases, 2017, 3, 5-17.	1.8	83
17	Identification of aminopyrimidineâ€sulfonamides as potent modulators of Wag31â€mediated cell elongation in mycobacteria. Molecular Microbiology, 2017, 103, 13-25.	1.2	22
18	Antitubercular drugs for an old target: GSK693 as a promising InhA direct inhibitor. EBioMedicine, 2016, 8, 291-301.	2.7	60

#	Article	IF	Citations
19	Phenotypic Heterogeneity in <i>Mycobacterium tuberculosis</i>. Microbiology Spectrum, 2016, 4, .	1.2	55
20	Stress and Host Immunity Amplify Mycobacterium tuberculosis Phenotypic Heterogeneity and Induce Nongrowing Metabolically Active Forms. Cell Host and Microbe, 2015, 17, 32-46.	5.1	264
21	Stressed Mycobacteria Use the Chaperone ClpB to Sequester Irreversibly Oxidized Proteins Asymmetrically Within and Between Cells. Cell Host and Microbe, 2015, 17, 178-190.	5.1	104
22	Rapid Cytolysis of Mycobacterium tuberculosis by Faropenem, an Orally Bioavailable Î²-Lactam Antibiotic. Antimicrobial Agents and Chemotherapy, 2015, 59, 1308-1319.	1.4	92
23	Bioluminescence for Assessing Drug Potency against Nonreplicating Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 2015, 59, 4012-4019.	1.4	30
24	Combinations of Î²-Lactam Antibiotics Currently in Clinical Trials Are Efficacious in a DHP-I-Deficient Mouse Model of Tuberculosis Infection. Antimicrobial Agents and Chemotherapy, 2015, 59, 4997-4999.	1.4	37
25	Whole Cell Target Engagement Identifies Novel Inhibitors of <i>Mycobacterium tuberculosis</i> Decaprenylphosphoryl-Î²-<scp>d</scp>-ribose Oxidase. ACS Infectious Diseases, 2015, 1, 615-626.	1.8	51
26	2-Carboxyquinoxalines Kill <i>Mycobacterium tuberculosis</i> through Noncovalent Inhibition of DprE1. ACS Chemical Biology, 2015, 10, 705-714.	1.6	116
27	Single-Cell Analysis of Mycobacteria Using Microfluidics and Time-Lapse Microscopy. Methods in Molecular Biology, 2015, 1285, 241-256.	0.4	18
28	Simple and Rapid Method To Determine Antimycobacterial Potency of Compounds by Using Autoluminescent Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 2014, 58, 5801-5808.	1.4	27
29	Erratum for Boldrin et al., The Phosphatidyl- <i>myo</i> -Inositol Mannosyltransferase PimA Is Essential for Mycobacterium tuberculosis Growth <i>In Vitro</i> and <i>In Vivo</i>. Journal of Bacteriology, 2014, 196, 4197-4197.	1.0	1
30	Delayed bactericidal response of Mycobacterium tuberculosis to bedaquiline involves remodelling of bacterial metabolism. Nature Communications, 2014, 5, 3369.	5.8	219
31	In VitroandIn VivoActivities of Three Oxazolidinones against Nonreplicating Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 2014, 58, 3217-3223.	1.4	53
32	<scp>EspI</scp> regulates the <scp>ESX</scp>â€1 secretion system in response to <scp>ATP</scp> levels in <scp><i>M</i></scp><i>ycobacterium tuberculosis</i>. Molecular Microbiology, 2014, 93, 1057-1065.	1.2	27
33	Assessing the essentiality of the decaprenylâ€phosphoâ€<scp>d</scp>â€arabinofuranose pathway in <scp><i>M</i></scp><i>ycobacterium tuberculosis</i> using conditional mutants. Molecular Microbiology, 2014, 92, 194-211.	1.2	76
34	The Phosphatidyl- <i>myo</i> -Inositol Mannosyltransferase PimA Is Essential for Mycobacterium tuberculosis Growth <i>In Vitro</i> and <i>In Vivo</i>. Journal of Bacteriology, 2014, 196, 3441-3451.	1.0	37
35	4-Aminoquinolone Piperidine Amides: Noncovalent Inhibitors of DprE1 with Long Residence Time and Potent Antimycobacterial Activity. Journal of Medicinal Chemistry, 2014, 57, 5419-5434.	2.9	97
36	Dielectrophoresis-based purification of antibiotic-treated bacterial subpopulations. Lab on A Chip, 2014, 14, 1850-1857.	3.1	61

#	Article	IF	Citations
37	<i><scp>M</scp>ycobacterium tuberculosis</i>â€…<scp>EspB</scp> binds phospholipids and mediates <scp>EsxA</scp>â€independent virulence. Molecular Microbiology, 2013, 89, 1154-1166.	1.2	65
38	Single-cell dynamics of the chromosome replication and cell division cycles in mycobacteria. Nature Communications, 2013, 4, 2470.	5.8	163
39	Dynamic Persistence of Antibiotic-Stressed Mycobacteria. Science, 2013, 339, 91-95.	6.0	495
40	Phenotypic Profiling of Mycobacterium tuberculosis EspA Point Mutants Reveals that Blockage of ESAT-6 and CFP-10 Secretion <i>In Vitro</i> Does Not Always Correlate with Attenuation of Virulence. Journal of Bacteriology, 2013, 195, 5421-5430.	1.0	47
41	Streptomycin-Starved Mycobacterium tuberculosis 18b, a Drug Discovery Tool for Latent Tuberculosis. Antimicrobial Agents and Chemotherapy, 2012, 56, 5782-5789.	1.4	88
42	Malachite Green Interferes with Postantibiotic Recovery of Mycobacteria. Antimicrobial Agents and Chemotherapy, 2012, 56, 3610-3614.	1.4	9
43	EspD Is Critical for the Virulence-Mediating ESX-1 Secretion System in Mycobacterium tuberculosis. Journal of Bacteriology, 2012, 194, 884-893.	1.0	66
44	Structural Basis for Benzothiazinone-Mediated Killing of <i>Mycobacterium tuberculosis</i>. Science Translational Medicine, 2012, 4, 150ra121.	5.8	159
45	Nanoparticle conjugation and pulmonary delivery enhance the protective efficacy of Ag85B and CpG against tuberculosis. Vaccine, 2011, 29, 6959-6966.	1.7	107
46	<i>Mycobacterium tuberculosis</i> persistence mutants identified by screening in isoniazid-treated mice. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 12275-12280.	3.3	110
47	Simple Model for Testing Drugs against Nonreplicating <i>Mycobacterium tuberculosis</i>. Antimicrobial Agents and Chemotherapy, 2010, 54, 4150-4158.	1.4	117
48	Development of a repressible mycobacterial promoter system based on two transcriptional repressors. Nucleic Acids Research, 2010, 38, e134-e134.	6.5	74
49	Boosting with a DNA vaccine expressing ESAT-6 (DNAE6) obliterates the protection imparted by recombinant BCG (rBCGE6) against aerosol Mycobacterium tuberculosis infection in guinea pigs. Vaccine, 2009, 28, 63-70.	1.7	22
50	Benzothiazinones Kill <i>Mycobacterium tuberculosis</i> by Blocking Arabinan Synthesis. Science, 2009, 324, 801-804.	6.0	660
51	Enhanced and Enduring Protection against Tuberculosis by Recombinant BCG-Ag85C and Its Association with Modulation of Cytokine Profile in Lung. PLoS ONE, 2008, 3, e3869.	1.1	58
52	Microbial phenotypic heterogeneity and antibiotic tolerance. Current Opinion in Microbiology, 2007, 10, 30-38.	2.3	279
53	Increased Expression of Mycobacterium tuberculosis 19 kDa Lipoprotein Obliterates the Protective Efficacy of BCG by Polarizing Host Immune Responses to the Th2 Subtype. Scandinavian Journal of Immunology, 2005, 61, 410-417.	1.3	22
54	Elicitation of efficient, protective immune responses by using DNA vaccines against tuberculosis. Vaccine, 2005, 23, 5655-5665.	1.7	37

#	Article	IF	Citations
55	Immunogenicity of recombinant BCG vaccine strains overexpressing components of the antigen 85 complex of Mycobacterium tuberculosis. Medical Microbiology and Immunology, 2004, 193, 19-25.	2.6	25
56	Skewing of the Th1/Th2 responses in mice due to variation in the level of expression of an antigen in a recombinant BCG system. Immunology Letters, 2003, 88, 175-184.	1.1	35
57	Disruption ofmptpBimpairs the ability ofMycobacterium tuberculosisto survive in guinea pigs. Molecular Microbiology, 2003, 50, 751-762.	1.2	174
58	Modulation of Host Immune Responses by Overexpression of Immunodominant Antigens of Mycobacterium tuberculosis in Bacille Calmette-Guerin. Scandinavian Journal of Immunology, 2003, 58, 449-461.	1.3	33
59	Recent Advances in Tuberculosis Research in India. Advances in Biochemical Engineering/Biotechnology, 2003, 84, 211-273.	0.6	3
60	Recombinant BCG approach for development of vaccines: cloning and expression of immunodominant antigens ofM. tuberculosis. FEMS Microbiology Letters, 2000, 190, 309-316.	0.7	29
61	Phenotypic Heterogeneity in<i>Mycobacterium tuberculosis</i>. , 0, , 671-697.		1